https://mc06.manuscriptcentral.com/cjpp-pubs quantitative insulin sensitivity check index, glucose) were determined in 48 (56% female) 38 healthy subjects. Heart-rate variability was calculated by spectral power analysis and 39 arterial stiffness was determined using noninvasive applanation tonometry. Both were 40 measured at baseline and in response to angiotensin II infusion. In women, there was a 41 non-statistically significant trend towards increasing insulin resistance being associated 42 with an overall unfavourable HRV response and increased arterial stiffness to the 
D r a f t
Sex differences in associations between insulin resistance, heart rate variability and 1 arterial stiffness in healthy women and men: a physiology study 2 Insulin resistance is a stronger cardiovascular risk in women compared to men (Oterdoom 57 et al. 2009 ). The risk factors for early cardiac autonomic impairment differ among 58 diabetic women and men (Nolan et al. 2009 ) and fasting insulin level is a stronger 59 determinant of arterial stiffness (Giltay et al. 1999 ) and cardiovascular outcomes 60 Similarly, while individuals with impaired fasting glucose have higher stress measures of 67 arterial stiffness, (Vasu et al. 2015) it is unknown whether this effect is modified by sex. 68
We sought to determine the association between insulin resistance and HRV and arterial 69 stiffness in healthy premenopausal women and men. 70
71

Methods 72
This study was approved by the University of Calgary Conjoint Health Research Ethics 73
Board. Subjects provided informed written consent. All subjects were healthy 74 normotensive, non-diabetic non-smokers and taking no prescription medications 75 (including oral contraceptives). Subjects underwent a medical history, physical 76 examination, and laboratory screening. Women were studied mid-menstrual cycle and 77 D r a f t none were on the oral contraceptive. All subjects maintained a high-salt state (>150 78 mmol/day) for 3 days prior to the study to ensure maximum renin angiotensin system 79 suppression (Shoback et al. 1983) . Compliance with the high-salt diet was verified by 80 measuring sodium excretion through a 24-h urine collection or a second morning void 81 spot urine (Kawasaki et al. 1993 ). Each study commenced at 0800h following an 82 overnight fast in a quiet, temperature-controlled room with subjects in a supine 83 position.Blood pressure was measured via an automated sphygmomanometer (Dinamap, 84 GE Healthcare, USA) every 15min. Subjects were infused intravenously with angiotensin 85 II (AngII) (3ng/kg/min×30min; 6ng/kg/min×30min). 86
Ambulatory electrocardiogram data were collected continuously (SEER MC 87 recorder, GE Healthcare). HRV frequency measures were calculated according to 88 standard methods (MARS version 7, GE Healthcare). Frequency domain parameters were 89 derived using power spectral analysis, where a combination of sympathetic and vagal 90 autonomic nervous system (ANS) power was represented by the low-frequency (LF; ms 2 ) 91 band within the range of 0.04-0.15 Hz, and vagal power was represented by the high-92 frequency (HF; ms 2 ) band within the range of 0.15-0.40 Hz, both of which were 93 expressed in normalized units (nu) to account for changes in total power. The LF:HF 94 The exploratory primary analysis examined the association between parameters of 118 insulin resistance (fasting insulin, HOMA-IR, HbA1c, QUICKI, glucose) and HRV and 119 arterial stiffness at baseline and in response to 60min AngII challenge, stratified by sex. 120
Baseline and response to AngII measures were compared using Student t-test. Women did not demonstrate any association between fasting glucose and any HRV 160 measure in response to AngII challenge. Men showed no association between glucose 161 and the change in LF in response to AngII but glucose was associated with the HF 162 response to AngII (r=0.34, p=0.046) and this was statistically different from women 163 (p=0.018). Results of the heart rate variability data are summarized in Table 2 . 164
Arterial Stiffness response to AngII 165
As anticipated, all subjects demonstrated a significant increase in measures of arterial 166 stiffness ( 
179
Discussion 180
Our findings were as follows: 1) in women, increasing insulin resistance was not 181 associated with a change in HRV in response to a physiologic stressor, whereas men 182 showed a decrease in LF, a marker of cardiosympathetic activity and an increase in HF, a 183 marker of protective cardiovagal input with increasing levels of insulin resistance; 2) 184 increasing insulin resistance was associated with a greater increase in stress-related 185 arterial stiffness in women but not men. Our results add to the mounting evidence that 186 important sex differences exist in the pathophysiology by which insulin resistance affects 187 cardiovascular risk. Endogenous sex hormones appear to play a role in mediating risk in the setting of 213 insulin resistance, with elevated levels of testosterone having opposing effects in men and 214 women (Ding et al. 2006 ). In older women, higher free testosterone levels were 215 D r a f t associated with greater insulin resistance (Oh et al. 2002) . A meta-analysis examining the 216 role of sex hormones in the risk of developing diabetes reported a higher risk of type 2 217 diabetes among women with increased testosterone levels, with the opposite association 218 in men (Ding et al. 2006 ). It was postulated that the elevated testosterone at the levels 219 increases adipose tissue in women and therefore may subsequently increase in insulin 220 resistance, however the exact mechanism remains unclear (Lovejoy et al. 1996) . 221
Similarly, low levels of sex-hormone binding globulin were associated with development 222 of diabetes in women but not in men, though a nested case-control study reported that 223 low circulating levels of sex hormone-binding globulin were a strong predictor of the risk 224 of type 2 diabetes in both women and men (Ding et al. 2006) . 225
The role of circulating estrogen levels as a risk for developing diabetes in women 226 and men is less clear. In a meta-analysis, estradiol levels were elevated among men and by which increased insulin resistance augments cardiovascular risk. With the exception of 253 one male subject with elevated fasting insulin levels, none of the subjects in our study 254 had evidence of the metabolic syndrome, which may explain the lack of association 255 observed between insulin resistance and baseline measures of HRV and arterial stiffness. 256
We speculate that in the earliest stages of insulin resistance only a stressor may uncover 257 abnormalities in cardiac autonomic and arterial tone as observed in our study. 258
Due to the cross-sectional nature of our study, we cannot demonstrate 259 directionality of the association nor comment on causality; it is possible that 260 D r a f t dysfunctional HRV or arterial stiffness caused an increase in insulin resistance in women, 261 although this would not explain why the same phenomenon did not occur in men. While 262 the study of healthy non-diabetic subjects limits the generalizability of the results, by 263 studying a normotensive, healthy population, we aimed to examine the impact of insulin 264 resistance and sex on HRV and measures of arterial stiffness while minimizing 265 confounding factors. Second, we attempted to minimize the effect of sample size and 266 intra-individual variability by utilizing a homogenous study group and careful pre-study 267 design. We ensured that all participants were ingesting similar amounts of salt to ensure 268 maximum RAS suppression, that no female participant was ingesting oral contraceptives, 269
and that all female subjects were studied during the same stage of the menstrual cycle, 270 during the follicular (low estrogen) stage to control for the effect of estrogen on blood 271 pressure and the RAS. In addition, all subjects were studied at the same time of the day, 272 while resting in the supine position in a warm, quiet room after an 8-h fast. We measured 273 insulin resistance using the HOMA model rather than a hyperinsulinemic-euglycemic 274 clamp. However, the HOMA model is a validated clinical and epidemiological tool 275 (Wallace et al. 2004 ). Furthermore, measures of insulin resistance were collected at 276 baseline and we were thus unable to account for any potential changes in insulin 277 sensitivity as a result of an Ang II infusion. However a study examining the effect of a 278 concurrent hyperinsulinemic clamp and Ang II infusion in healthy non-diabetic stubjects 279 did not report any change to overall insulin sensitivity (Jonk et al. 2010) . In a study of 280 healthy men and women, it was reported that random error represented a limited part of 281 the between-subject variability; therefore observed differences between individuals 282 mostly reflect differences in the subjects' error-free value rather than random error (Pinna 
